Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement
Sriram Deivasigamani,Srinath Kotamarti,Ardeshir R. Rastinehad,Rafael Sanchez Salas,J.J.M.C.H. de la Rosette,Herbert Lepor,Peter Pinto,Hashim U. Ahmed,Inderbir Gill,Laurence Klotz,Samir S. Taneja,Mark Emberton,Nathan Lawrentschuk,James Wysock,John F. Feller,Sebastien Crouzet,Praveen Kumar M.,Denis Seguier,Eric S. Adams,Zoe Michael,Andre Abreu,Kae Jack Tay,John F. Ward,Katsuto Shinohara,Aaron E. Katz,Arnauld Villers,Joseph L. Chin,Phillip D. Stricker,Eduard Baco,Petr Macek,Ardalan E. Ahmad,Peter K.F. Chiu,E. David Crawford,Craig G. Rogers,Jurgen J. Futterer,Soroush Rais-Bahrami,Cary N. Robertson,Boris Hadaschik,Giancarlo Marra,Massimo Valerio,Kian Tai Chong,Veeru Kasivisvanathan,Wei Phin Tan,Derek Lomas,Jochen Walz,Gustavo Cardoso Guimaraes,Nikos I. Mertziotis,Ezequiel Becher,Antonio Finelli,Ali Kasraeian,Amir H. Lebastchi,Anup Vora,Mark A. Rosen,Baris Bakir,Rohit Arcot,Samuel Yee,Christopher Netsch,Xiaosong Meng,Theo M. de Reijke,Yu Guang Tan,Stefano Regusci,Tavya G.R. Benjamin,Ruben Olivares,Mohamed Noureldin,Fernando J. Bianco,Arjun Sivaraman,Fernando J. Kim,Robert W. Given,Shawn Dason,Tyler J. Sheetz,Sunao Shoji,Ariel Schulman,Peter Royce,Taimur T. Shah,Stephen Scionti,Georg Salomon,Pilar Laguna,Rafael Tourinho-Barbosa,Alireza Aminsharifi,Xavier Cathelineau,Paolo Gontero,Armando Stabile,Jeremy Grummet,Leila Ledbetter,Margaret Graton,J. Stephen Jones,Thomas J. Polascik,Focal Therapy Society
DOI: https://doi.org/10.1016/j.eururo.2023.06.013
IF: 24.267
2023-07-01
European Urology
Abstract:CONTEXT: Whole-gland ablation is a feasible and effective minimally invasive treatment for localized prostate cancer (PCa). Previous systematic reviews supported evidence for favorable functional outcomes, but oncological outcomes were inconclusive owing to limited follow-up.OBJECTIVE: To evaluate the real-world data on the mid- to long-term oncological and functional outcomes of whole-gland cryoablation and high-intensity focused ultrasound (HIFU) in patients with clinically localized PCa, and to provide expert recommendations and commentary on these findings.EVIDENCE ACQUISITION: We performed a systematic review of PubMed, Embase, and Cochrane Library publications through February 2022 according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. As endpoints, baseline clinical characteristics, and oncological and functional outcomes were assessed. To estimate the pooled prevalence of oncological, functional, and toxicity outcomes, and to quantify and explain the heterogeneity, random-effect meta-analyses and meta-regression analyses were performed.EVIDENCE SYNTHESIS: Twenty-nine studies were identified, including 14 on cryoablation and 15 on HIFU with a median follow-up of 72 mo. Most of the studies were retrospective (n = 23), with IDEAL (idea, development, exploration, assessment, and long-term study) stage 2b (n = 20) being most common. Biochemical recurrence-free survival, cancer-specific survival, overall survival, recurrence-free survival, and metastasis-free survival rates at 10 yr were 58%, 96%, 63%, 71-79%, and 84%, respectively. Erectile function was preserved in 37% of cases, and overall pad-free continence was achieved in 96% of cases, with a 1-yr rate of 97.4-98.8%. The rates of stricture, urinary retention, urinary tract infection, rectourethral fistula, and sepsis were observed to be 11%, 9.5%, 8%, 0.7%, and 0.8%, respectively.CONCLUSIONS: The mid- to long-term real-world data, and the safety profiles of cryoablation and HIFU are sound to support and be offered as primary treatment for appropriate patients with localized PCa. When compared with other existing treatment modalities for PCa, these ablative therapies provide nearly equivalent intermediate- to long-term oncological and toxicity outcomes, as well as excellent pad-free continence rates in the primary setting. This real-world clinical evidence provides long-term oncological and functional outcomes that enhance shared decision-making when balancing risks and expected outcomes that reflect patient preferences and values.PATIENT SUMMARY: Cryoablation and high-intensity focused ultrasound are minimally invasive treatments available to selectively treat localized prostate cancer, considering their nearly comparable intermediate- to long term cancer control and preservation of urinary continence to other radical treatments in the primary setting. However, a well-informed decision should be made based on one's values and preferences.
urology & nephrology